NCT06101277Recruiting
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 19 Oct 2023
- Start date
- 5 Oct 2023
- Primary completion date
- 5 Dec 2033
- Lead sponsor
- University of California, Davis
- NCT number
- NCT06101277
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 5 Oct 2023 to the primary completion date, 5 Dec 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medical comorbidities precluding locally ablative therapies.
Other illness
- History of treatment related toxicities that limit or prohibit application of locally ablative therapies.
Other
- Progressing intracranial lesions.
Who the study is looking for
- Must have one of the following histologically and/or biochemically confirmed cancers:
- Cohort A: (Cohort removed in protocol version 4.0)
- Cohort B: Small bowel
- Cohort C: Pancreatic and ampullary, colorectal, and appendiceal
- Cohort D: (Cohort removed in protocol version 4.0)
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Age ≥18 years at time of consent.
- Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.
- ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\]
- ≤ 5 progressing or new metastatic lesions.
- All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California Davis Comprehensive Cancer Center Coordinator of this site? Confirm its status | Sacramento | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.